Emergent Biosolutions has successfully obtained a contract modification worth approximately $52.7 million from the U.S. government, involving ACAM2000® smallpox and monkeypox (vaccinia) live vaccines.

This major contract adjustment highlights the company’s ongoing critical role in the field of public health security. The confirmation of the contract amount not only provides stable financial support for the company’s related product lines, but also further strengthens its long-term partnership with U.S. government departments. The revision is expected to boost the production and supply of the vaccine, addressing potential public health needs.